公开(公告)号：US20240344019A1

公开(公告)日：2024-10-17

申请号：US18294013

申请日：2022-08-17

Applicant: SK BIOSCIENCE CO., LTD.

Inventor： Jin Hwan SHIN ,  Young Joon CHOI ,  Hun KIM ,  Yong-min KWON ,  Hye-won JEONG

IPC: C12N1/20 ,  C12N1/04

CPC classification number: C12N1/205 ,  C12N1/04 ,  C12N2510/02 ,  C12N2511/00 ,  C12N2523/00 ,  C12N2830/50

Abstract: The present invention relates to a method for stably maintaining a poly(A) tail.

公开(公告)号：US20240301092A1

公开(公告)日：2024-09-12

申请号：US18575016

申请日：2022-06-29

Applicant: TEGA Therapeutics, Inc.

Inventor： Bryan E. THACKER ,  Jeffrey D. ESKO ,  Charles A. GLASS

IPC: C08B37/00 ,  A61K31/727 ,  C08L5/10 ,  C12N5/00 ,  C12N5/0787 ,  C12N9/10

CPC classification number: C08B37/0075 ,  A61K31/727 ,  C08L5/10 ,  C12N5/0018 ,  C12N5/0642 ,  C12N9/13 ,  C12N2500/34 ,  C12N2510/02 ,  C12N2511/00

Abstract: Provided herein are methods of producing heparin and heparan sulfate from modified cells, such as modified MST cells, and compositions comprising heparin and heparan sulfate isolated from modified cells.

公开(公告)号：US12031156B2

公开(公告)日：2024-07-09

申请号：US16872419

申请日：2020-05-12

Applicant: TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  A61K35/12

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5156 ,  A61K2039/585 ,  C12N2501/515 ,  C12N2510/02 ,  C12N2511/00

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US20240174748A1

公开(公告)日：2024-05-30

申请号：US18432126

申请日：2024-02-05

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  NADIA ANCERIZ ,  ARIANE MOREL ,  BENJAMIN ROSSI

IPC: C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66

CPC classification number: C07K16/2803 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/468 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/526 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/92 ,  C12N2511/00 ,  C12N2523/00

Abstract: The application pertains to NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US11970724B2

公开(公告)日：2024-04-30

申请号：US17370389

申请日：2021-07-08

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Shadia Abike Oshodi ,  Amy S. Johnson ,  Shawn M. Lawrence

IPC: C12P21/00 ,  C07K16/18 ,  C12N5/00 ,  C12N5/071

CPC classification number: C12P21/00 ,  C07K16/18 ,  C12N5/0031 ,  C12N5/0037 ,  C12N5/0043 ,  C12N5/005 ,  C12N5/0682 ,  C12N2500/22 ,  C12N2500/24 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2500/46 ,  C12N2510/02 ,  C12N2511/00

Abstract: The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.

公开(公告)号：US20230365920A1

公开(公告)日：2023-11-16

申请号：US18359240

申请日：2023-07-26

Applicant: Wyeth LLC

Inventor： Gregory Walter HILLER

IPC: C12N5/00 ,  C12P21/00 ,  C12N5/071 ,  C12M1/00

CPC classification number: C12N5/0018 ,  C12P21/00 ,  C12N5/0682 ,  C12M47/10 ,  C12M29/18 ,  C12M29/16 ,  C12N2511/00

Abstract: The invention relates to methods of improving protein production, e.g., large-scale commercial protein production, e.g., antibody production, utilizing a modified fed-batch cell culture method comprising a cell growth phase and a polypeptide production phase. The modified fed-batch cell culture method combines both cell culture perfusion and fed-batch methods to achieve higher titers of polypeptide products. Because the modified fed-batch cell culture method of the invention produces higher polypeptide product titers than fed-batch culture alone, it will substantially improve commercial-scale protein production. The invention also relates to a perfusion bioreactor apparatus comprising a fresh medium reservoir connected to a bioreactor by a feed pump, a recirculation loop connected to the bioreactor, wherein the recirculation loop comprises a filtration device, e.g., ultrafiltration or microfiltration, and a permeate pump connecting the filtration device to a permeate collection container.

公开(公告)号：US20230272346A1

公开(公告)日：2023-08-31

申请号：US18046083

申请日：2022-10-12

Applicant: Upside Foods, Inc.

Inventor： Nicholas J. GENOVESE ,  Meri Teresa FIRPO ,  Daphné DAMBOURNET

IPC: C12N5/077 ,  C07K14/47

CPC classification number: C12N5/0658 ,  C07K14/4703 ,  C12N5/0656 ,  C12N2501/998 ,  C12N2511/00

Abstract: Provided herein are methods to increase the culture density and/or thickness of a cellular biomass in a cultivation infrastructure, to improve the culture of cells in the absence of serum in a cultivation infrastructure, and to promote anchorage-independent growth of a cellular biomass in a cultivation infrastructure. The methods comprise inhibiting the HIPPO signaling pathway, for example, by activating YAP1, activating TAZ, and/or inhibiting MOB1, LATS1 kinase, LATS2 kinase, WW45, MST1 kinase, and/or MST2 kinase in the cellular biomass. In some embodiments, the cellular biomass is harvested from the cultivation infrastructure for the formulation of cell-based food products or ingredients, such as animal meat manufactured from cells in an ex vivo process or for therapeutic applications such as organ or tissue transplantation or grafting.

公开(公告)号：US20230257702A1

公开(公告)日：2023-08-17

申请号：US18010372

申请日：2021-03-05

Applicant: Da Witt KANG ,  HANMOBIO CO., LTD. ,  HANBIO CO., LTD.

Inventor： Da Witt KANG ,  Jung In YOON ,  Jeong Won RHO

IPC: C12N5/071

CPC classification number: C12N5/0628 ,  C12N2501/115 ,  C12N2511/00 ,  C12N2509/10

Abstract: Provided is a method for isolation and expansion of dermal papilla cells, and more particularly, to a method of isolating dermal papilla cells from hair bulbs, isolated from scalp tissue, by chopping, and then expanding the isolated dermal papilla cells by passaging. The expanded dermal papilla cells may play an important role in hair growth, and thus the present invention may be used in various industrial fields, including the medical field and the cosmetic field.

公开(公告)号：US11718864B2

公开(公告)日：2023-08-08

申请号：US16917099

申请日：2020-06-30

Applicant: PFIZER INC.

Inventor： Gregory Walter Hiller ,  Jeffrey Joseph Mitchell ,  Bhanu Chandra Mulukutla ,  Pamela Mary Pegman

IPC: C12N15/62 ,  C12P7/62 ,  C12P7/42 ,  C12P7/52 ,  C07K16/00 ,  C12P7/56 ,  C12P7/40 ,  C12P17/18

CPC classification number: C12P7/62 ,  C07K16/00 ,  C12P7/40 ,  C12P7/42 ,  C12P7/52 ,  C12P7/56 ,  C12P17/182 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2510/00 ,  C12N2510/02 ,  C12N2511/00

Abstract: The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.

公开(公告)号：US11672855B2

公开(公告)日：2023-06-13

申请号：US17035451

申请日：2020-09-28

Applicant: NATIONAL HEALTH RESEARCH INSTITUTES ,  FUJIFILM IRVINE SCIENTIFIC, INC.

Inventor： Jenny Bang ,  Hsiao-Tzu Ni ,  Alan Yung-Chih Hu ,  Tsai-Chuan Weng

IPC: C12N5/00 ,  A61K39/145 ,  A61K39/12 ,  C12N5/071 ,  C12N7/00 ,  C12N15/85 ,  A61P31/16

CPC classification number: A61K39/145 ,  A61K39/12 ,  C12N5/0686 ,  C12N7/00 ,  C12N15/8509 ,  A61P31/16 ,  C12N2015/8518 ,  C12N2500/90 ,  C12N2500/99 ,  C12N2511/00 ,  C12N2513/00 ,  C12N2517/02 ,  C12N2760/16034 ,  C12N2760/16051 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16251

Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.